N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
← catalyst calendarNCT06061809 · readout in 1,230 d
Sponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
34estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-07 | actual | When the study began enrolling |
| Primary completion | 2029-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glioblastoma
Interventions
- Drug: Bevacizumab — also filed as Avastin
- Drug: PD-L1 t-haNK
- Drug: N-803 — also filed as ALT-803, Anktiva
- Device: Tumor Treating Fields (TTFields, 200 kHz)
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
measured From beginning of Cycle 1 (each cycle is 28 days) to 30 days after end of treatment study visit.
Incidence of clinically significant changes in comprehensive metabolic panel (CMP)
measured From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and each subsequent treatment Cycle on Days 1 and Day 15 and at the end of treatment study visit.
Incidence of clinically significant changes in Hematology blood panel.
measured From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and each subsequent treatment Cycle on Days 1 and Day 15 and at the end of treatment study visit.
Incidence of clinically significant changes in Urinalysis.
measured From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and each subsequent treatment Cycle on Days 1 and Day 15 and at the end of treatment study visit.
12-lead Electrocardiogram (ECG)
measured From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and each subsequent Cycle Day1 through to the end of treatment study visit.
Incidence of clinically significant changes in Temperature
measured From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and Cycle 2 on days 1, 2 and 15, followed by each subsequent treatment Cycle on Days 1 and 15 and on the end of treatment study visit.
Incidence of clinically significant changes in Heart Rate
measured From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and Cycle 2 on days 1, 2 and 15, followed by each subsequent treatment Cycle on Days 1 and 15 and on the end of treatment study visit.
Incidence of clinically significant changes in Respiratory Rate
measured From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and Cycle 2 on days 1, 2 and 15, followed by each subsequent treatment Cycle on Days 1 and 15 and on the end of treatment study visit.
Incidence of clinically significant changes in Blood Pressure
measured From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and Cycle 2 on days 1, 2 and 15, followed by each subsequent treatment Cycle on Days 1 and 15 and on the end of treatment study visit.
Incidence of clinically significant changes in Oxygen Saturation
measured From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and Cycle 2 on days 1, 2 and 15, followed by each subsequent treatment Cycle on Days 1 and 15 and on the end of treatment study visit.
Neurological assessment to grade Immune effector cell-associated neurotoxicity syndrome (ICANS)
measured On Cycle 1 (each cycle is 28 days) Day1, Day2, Day 15 and Day16, followed by each subsequent treatment Cycle on Days 1 and 15. Collection stops at the end of treatment study visit.
Safety assessed by Cytokine Levels
measured From Cycle 1 (each cycle is 28 days) Day1, Day2, Day 15 and Day16, followed by each subsequent treatment Cycle on Day 1. Collection stops at the end of treatment study visit.
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed